Please wait a minute...
ZJUS-B
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2014, Vol. 15 Issue (1): 1-15    DOI: 10.1631/jzus.B1300264
Reviews     
Harnessing the immune system for the treatment of breast cancer
Xinguo Jiang
Department of Medicine, VA Palo Alto Health Care System/Stanford University School of Medicine, Stanford, CA 94305, USA
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Standard treatment options for breast cancer include surgery, chemotherapy, radiation, and targeted therapies, such as adjuvant hormonal therapy and monoclonal antibodies. Recently, the recognition that chronic inflammation in the tumor microenvironment promotes tumor growth and survival during different stages of breast cancer development has led to the development of novel immunotherapies. Several immunotherapeutic strategies have been studied both preclinically and clinically and already have been shown to enhance the efficacy of conventional treatment modalities. Therefore, therapies targeting the immune system may represent a promising next-generation approach for the treatment of breast cancers. This review will discuss recent findings that elucidate the roles of suppressive immune cells and proinflammatory cytokines and chemokines in the tumor-promoting microenvironment, and the most current immunotherapeutic strategies in breast cancer.

Key words： Breast cancer      Chronic inflammation      Protumorigenic immune cells      Therapeutic vaccines      Immunotherapy     
Received: 20 October 2013      Published: 04 January 2014
CLC:  R737.9  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Xinguo Jiang
Cite this article:

Xinguo Jiang. Harnessing the immune system for the treatment of breast cancer. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(1): 1-15.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B1300264     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2014/V15/I1/1

[1] Shi-chong Liao, Jin-xin Li, Li Yu, Sheng-rong Sun. Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(4): 334-342.
[2] Shu-min Liu, Shi-yi Ou, Hui-hua Huang. Green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(2): 89-98.
[3] Ming Zhao, Xian-feng Ding, Jian-yu Shen, Xi-ping Zhang, Xiao-wen Ding, Bin Xu. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 15-26.
[4] Chun-xi Wang, Shu-li Guo, Li-na Han. Successful treatment of accessory breast cancer with endocrine therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 70-75.
[5] Xiao-peng Lan, You-gen Chen, Zheng Wang, Chuan-wei Yuan, Gang-gang Wang, Guo-liang Lu, Shao-wei Mao, Xun-bo Jin, Qing-hua Xia. Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(9): 743-756.
[6] Sabrina Mattoli. Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(8): 651-660.
[7] Hui-ying Wang, Yi-hong Shen, Xu-yan Yang, Lan-fang Tang, Jian-ying Zhou, on behalf of the Zhejiang Provincial Academy of Allergy . Diagnosis and treatment of allergic diseases in Zhejiang Province: a cross-sectional survey[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(7): 640-650.
[8] Zhao-ji Liu, Gregg L. Semenza, Hua-feng Zhang. Hypoxia-inducible factor 1 and breast cancer metastasis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 32-43.
[9] Xinguo Jiang. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 44-45.
[10] Hui-xin Liu, Xiao-li Li, Chen-fang Dong. Epigenetic and metabolic regulation of breast cancer stem cells[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 10-17.
[11] Wei Wang, Yun-ping Luo. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 18-31.
[12] Chai-Hong Yeong, Mu-hua Cheng, Kwan-Hoong Ng. Therapeutic radionuclides in nuclear medicine: current and future prospects[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(10): 845-863.
[13] Sheereen Tarannum, Zarina Arif, Khursheed Alam. Binding of circulating autoantibodies in breast cancer to native and peroxynitrite-modified RNA[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(1): 40-46.
[14] Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2011, 12(3): 174-179.
[15] Yi ZHENG, Jing ZHANG, Zhen-zhen XU,Jian-ming SHENG, Xiao-chen ZHANG, Hao-hao WANG, Xiao-dong TENG, Xiao-jiao LIU, Jiang CAO, Li-song TENG. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2010, 11(2): 144-150.